Small molecule melanin-concentrating hormone receptor 1 (MCH1R) antagonists as anxiolytic and antidepressive agents

Drug Development Research

Volumn 65, Issue 4, 2005, Pages 291-300

  Dyck, Brian ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Anxiety; Depression; Melanin concentrating hormone

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ATC 0065; ATC 0175; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; GLUTAMIC ACID; HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; MELANIN CONCENTRATING HORMONE; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; N (6 DIMETHYLAMINOMETHYL 5,6,7,8 TETRAHYDRO 2 NAPHTHYL) 4' FLUORO 1,1' BIPHENYL 4 CARBOXAMIDE; NEUROPEPTIDE RECEPTOR; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; QUINAZOLINE DERIVATIVE; RECEPTOR SUBTYPE; SB 568849; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; SNAP 7941; SNAP 94847; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY; ANXIETY DISORDER; CLINICAL TRIAL; DEPRESSION; DRUG CONTRAINDICATION; DRUG EFFICACY; ENERGY EXPENDITURE; FORCED SWIMMING TEST; GENE; HUMAN; NONHUMAN; OBESITY; PHENOTYPE; REVIEW; STRESS; TRANQUILIZING ACTIVITY; WEIGHT GAIN;

EID: 29544433086     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.20030     Document Type: Review

References (92)

1. Adamantidis A, Thomas E, Foidart A, Typhon A, Coumans B, Minet A, Tirelli E, Seutin V, Grisar T, Lakaye B. 2005. Disrupting the melanin-concentrating hormone receptor 1 in mice leads to cognitive deficits and alterations of NMDA receptor function. Eur J Neurosci 21:2837-2844.
2. Amgen. 2005. Available on line at www.amgen.com/science/pipe_AMG076.html.
3. An S, Cutler G, Zhao JJ, Huang S-G, Tian H, Li W, Liang L, Rich M, Bakleh A, Du J, Chen J-L, Dai K. 2001. Identification and characterization of a melanin-concentrating hormone receptor. Proc Natl Acad Sci USA 98:7576-7581.
4. Appolinario JC, Bueno JR, Coutinho W. 2004. Psychotropic drugs in the treatment of obesity. What promise? CNS Drugs 18:629-651.
5. Artigas F, Celada P, Laruelle M, Adell A. 2001. How does pindolol improve antidepressant action? Trends Pharmacol Sci 22:224-228.
6. Astrand A, Bohlooly-Y M, Larsdotter S, Mahlapuu M, Andersén H, Tornell J, Ohlsson C, Snaith M, Morgan DGA. 2004. Mice lacking melanin-concentrating hormone receptor 1 demonstrate increased heart rate associated with altered autonomic activity. Am J Physiol Regul Integr Comp Physiol 287:R749-R758.
7. Bednarek MA, Hreniuk DL, Tan C, Palyha OC, MacNeil DJ, Van der Ploeg LHY, Howard AD, Feighner SD. 2002. Synthesis and biological evaluation in vitro of selective, high affinity peptide antagonists of human melanin-concentrating hormone action at human melanin-concentrating hormone receptor 1. Biochemistry 41:6383-6390.
8. Bittencourt JC, Presse F, Arias C, Peto C, Vaughan J, Nahon J-L, Vale W, Sawchenko PE. 1992. The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization. J Comp Neurol 319:218-245.
9. Bluet-Pajot M-T, Presse F, Voko Z, Hoeger C, Mounier F, Epelbaum J, Nahon J-L. 1995. Neuropeptide-E-I antagonizes the action of melanin-concentrating hormone on stress-induced release of adrenocorticotropin in the rat. J Neuroendocrinol 7:297-303.
10. Bohlooly-Y M, Mahlapuu M, Andersén H, Astrand A, Hjorth S, Svensson L, Tornell J, Snaith MR, Morgan DG, Ohlsson C. 2004. Osteoporosis in MCHR1-deficient mice. Biochem Biophys Res Commun 318:964-969.
11. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I, Blackburn TP, Branchek TA, Gerald C, Vaysse PJ, Forray C. 2002. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 8:825-830.
12. Borsini F, Podhorna J, Marazziti D. 2002. Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 163:121-141.
13. Bosker FJ, Westerink BHC, Cremers TIFH, Gerrits M, van der Hart MGC, Kuipers SD, van der Pompe G, ter Horst GJ, den Boer JA, Korf J. 2004. Future antidepressants. What is in the pipeline and what is missing? CNS Drugs 18:705-732.
14. Chaki S, Funakoshi T, Hirota-Okuno S, Nishiguchi M, Shimazaki T, Iijima M, Grottick AJ, Kanuma K, Omodera K, Sekiguchi Y, Okuyama S, Tran T-A, Semple G, Thomsen W. 2005. Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J Pharmacol Exp Ther 313:831-839.
15. Chambers J, Ames RS, Bergsma D, Muir A, Fitzgerald LR, Hervieu G, Dytko GM, Foley JJ, Martin J, Lin W-S, Park J, Ellis C, Ganguly S, Konchar S, Cluderay J, Leslie R, Wilson S, Saran HM. 1999. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature 400:261-265.
16. Chen Y, Hu C, Hsu C-K, Zhang Q, Bi C, Asnicar M, Hsiung HM, Fox N, Slieker LJ, Yang DD, Heiman ML, Shi Y. 2002. Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology 143:2469-2477.
17. Clegg DJ, Air EL, Benoit SC, Sakai RS, Seeley RJ, Woods SC. 2003. Intraventricular melanin-concentrating hormone stimulates water intake independent of food intake. Am J Physiol Regul Integr Comp Physiol 284:R494-R499.
18. Collins CA, Kym PR. 2003. Prospects for obesity treatment: MCH receptor antagonists. Curr Opin Investig Drugs 4:386-394.
19. Corey-Lisle PK, Nash R, Stang P, Swindle R. 2004. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 164:1197-1204.
20. Della-Znana O, Presse F, Ortola C, Dubault J, Nahon JL, Levens N. 2002. Acute and chronic administration of melanin-concentrating hormone enhances food intake and body weight in Wistar and Sprague-Dawley rats. Int J Obesity 26:1289-1295.
21. Detke MJ, Wieland S, Lucki I. 1995. Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by 5HT1A receptor antagonists. Psychopharmacology (Berl) 119:47-54.
22. Drazen DL, Coolen LM, Strader AD, Wortman MD, Woods SC, Seeley RJ. 2004. Differential effects of adrenalectomy on melanin-concentrating hormone and orexin A. Endocrinology 145:3404-3412.
23. Dymek MP, le Grange D, Neven K, Alverdy J. 2001. Quality of life and psychosocial adjustment in patients after Roux-en-Y gastric bypass: a brief report. Obes Surg 11:32-39.
24. Georgescu D, Sears RM, Hommel JD, Barrot M, Bolaños CA, Marsh DJ, Bednarek MA, Bibb JA, Maratos-Flier E, Nestler EJ, DiLeone RJ. 2005. The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performance. J Neurosci 25:2933-2940.
25. Gladis MM, Wadden TA, Vogt R, Foster G, Kuehnel RH, Bartlett SJ. 1998. Behavioral treatment of obese binge eaters: do they need different care? J Psychosom Res 44:375-384.
26. GlaxoSmithKline. 2005. Available on line at www.gsk.com/financial/ product_pipe-line.html.
27. Gonzalez MI, Vaziri S, Wilson CA. 1996. Behavioral effects of α-MSH and MCH after central administration in the female rat. Peptides 17:171-177.
28. Gonzalez MI, Baker BI, Hole DR, Wilson CA. 1998. Behavioral effects of neuropeptide E-I (NEI) in the female rat: interactions with α-MSH, MCH and dopamine. Peptides 19:1007-1016.
29. Goodwin GM. 1996. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of SSRIs. J Clin Psychiatry 57(Suppl 4):9-13.
30. Hervien GJ, Cluderay JE, Harrison D, Meakin J, Maycox P, Nasir S, Leslie RA. 2000. The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat. Eur J Neurosci 12:1194-1216.
31. 2, a novel human MCH receptor. J Biol Chem 276:20125-20129.
32. Ho Y-J, Eichendorff J, Schwarting RKW. 2002. Individual response profiles of male Wistar rats in animal models for anxiety and depression. Behav Brain Res 136:1-12.
33. Holsboer F. 2004. Therapeutics for depression and anxiety disorders. Drug Discovery Today: Therapeutic Strategies 1:1-5.
34. Huang CQ, Baker T, Schwarz D, Fan J, Heise CE, Zhang M, Goodfellow VS, Markison S, Gogas KR, Chen T, Wang X-C, Saunders J, Zhu Y-F. 2005. 1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)- pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists. Bioorg Med Chem Lett 16:3701-3706.
35. Husbands SM, Izenwasser S, Kopajtic T, Bowen WD, Vilner BJ, Katz JL, Newman AH. 1999. Structure-activity relationships at the monoamine transporters and σ receptors for a novel series of 9-[3-(cis-3,5-dimethyl-1- piperazinyl)-propyl]carbazole (rimcazole) analogues. J Med Chem 42:4446-4455.
36. IDdb3. 2005. MCH-1 receptor antagonists, Lundbeck. The Investigational Drug Database Drug Report. Available on line at www.iddb3.com.
37. Ishihara Y, Kamata M, Takekawa S, Suzuki N, Kato K. 2003. WO 03/035624 A1.
38. Jezova D, Bartanusz V, Westergren I, Johansson BB, Rivier J, Vale W, Rivier C. 1992. Rat melanin-concentrating hormone stimulates adrenocorticotropin secretion: evidence for a site of action in brain regions protected by the blood-brain barrier. Endocrinology 130:1024-1029.
39. Johnson AL, File SE. 1991. Sex differences in animal tests of anxiety. Physiol Behav 49:245-250.
40. 1A receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation. J Med Chem 47:2659-2666.
41. Kela J, Salmi P, Rimondini-Giorgini R, Heilig M, Wahlestedt C. 2003. Behavioural analysis of melanin-concentrating hormone in rats: evidence for orexigenic and anxiolytic properties. Regul Pept 114:109-114.
42. Kennedy AR, Todd JF, Dhillo WS, Seal LJ, Ghatei MA, O'Toole CP, Jones M, Witty D, Winborne K, Riley G, Hervieu G, Wilson S, Bloom SR. 2003. Effect of direct injection of melanin-concentrating hormone into the paraventricular nucleus: further evidence for a stimulatory role in the adrenal axis via SLC-1. J Neuroendocrinol 15:268-272.
43. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the national comorbidity survey. Arch Gen Psychiatry 51:8-19.
44. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. 2003. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 289:3095-3105.
45. Kowalski TJ, McBriar MD. 2004. Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. Expert Opin Investig Drugs 13:1113-1122.
46. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NMJ. 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645.
47. Krase W, Koch M, Schnitzler H-U. 1994. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats. Behav Brain Res 63:81-88.
48. Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P. 2001. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40:1028-1033.
49. Lucki I. 1997. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8:523-532.
50. Marsh DJ, Weingarth DT, Novi DE, Chen HY, Trumbauer ME, Chen AS, Guan X-M, Jiang MM, Feng Y, Camacho RE, Shen Z, Easter FG, Yu H, Metzger JM, Kuca SJ, Shearman LP, Gopal-Truter S, MacNeil DJ, Strack AM, MacIntyre DE, Van der Ploeg LHT, Qian S. 2002. Melanin-concentrating hormone I receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA 99:3240-3245.
51. 1A serotonin receptors and serotonin transporter, as a new class of antidepressants. J Med Chem 44:418-428.
52. Marzabadi MR, Wetzel JM, Chen C-A, Jiang Y, Lu K. 2004a. Substituted alkyl amido piperidines. US 2004/0073036.
53. Marzabadi MR, Wetzel J, Deleon JE, Jiang Y, Chen C-A, Lu K. 2004b. Substituted anilinic piperidines as MCH selective antagonists. US 6,727,264 B1.
54. McBriar MD, Guzik H, Xu R, Paruchova J, Li S, Palani A, Clader JW, Greenlee WJ, Hawes BE, Kowalksi TJ, O'Neill K, Spar B, Weig B. 2005. Discovery of bicycloalkyl urea melanin concentrating hormone receptor antagonists: orally efficacious antiobesity therapeutics. J Med Chem 48:2274-2277.
55. 1 receptor antagonist, (+)SNAP-7941, in models of potential antidepressant and anxiolytic activity in rodents. Eur J Neuropsychopharmacol 13(Suppl 4):S268.
56. Monzón ME, De Barioglio SR. 1999. Response to novelty after i.c.v injection of melanin-concentrating hormone (MCH) in rats. Physiol Behav 67:813-817.
57. Monzón ME, Varas MM, De Barioglio SR. 2001. Anxiogenesis induced by nitric oxide synthase inhibition and anxiolytic effect of melanin-concentrating hormone (MCH) in rat brain. Peptides 22:1043-1047.
58. 1. Biochem Biophys Res Commun 283:1013-1018.
59. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. 2002. Neurobiology of depression. Neuron 34:13-25.
60. Nibuya M, Morinobu S, Duman RS. 1995. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539-7547.
61. Pacher P, Kecskemeti V. 2004. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr Med Chem 11:925-943.
62. Palani A, Shapiro S, McBriar MD, Clader JW, Greenlee WJ, Spar B, Kowalski TJ, Farley C, Cook J, van Heek M, Weig B, O'Neill K, Graziano M, Hawes B. 2005. Biaryl ureas as potent and orally efficacious melanin concentrating hormone receptor 1 antagonists for the treatment of obesity. J Med Chem 48:4746-4749.
63. Palanza P. 2001. Animal models of anxiety and depression: how are females different? Neurosci Biobehav Rev 25:219-233.
64. Poindexter GS, Bruce MA, LeBoulluee KL, Monkovic I, Martin SW, Parker EM, Iben LG, McGovern RT, Ortiz AA, Stanley JA, Mattson GK, Kozlowski M, Arcuri M, Antal-Zimanyi I. 2002. Dihydropyridine neuropeptide Y Y1 receptor antagonists. Bioorg Med Chem Lett 12:379-382.
65. Presse F, Hervien G, Imaki T, Sawchenko PE, Vale W, Nahon J-L. 1992. Rat melanin-concentrating hormone messenger ribonucleic acid expression: marked changes during development and after stress and glucocorticoid stimuli. Endocrinology 131:1241-1250.
66. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ, Mathes WF, Przypek J, Kanarek R, Maratos-Flier E. 1996. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 380:243-247.
67. Ressler KJ, Nermeroff CB. 2000. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12(Suppl I):2-19.
68. Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, Huganir RL. 1996. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16:1179-1188.
69. Rodgers RJ, Cao B-J, Dalvi A, Holmes A. 1997. Animal models of anxiety: an ethological perspective. Braz J Med Biol Res 30:289-304.
70. Rodriguez M, Beauverger P, Naime I, Rique H, Ouvry C, Souchand S, Dromaint S, Nagel N, Suply T, Audinot V, Boutin JA, Galizzi JP. 2001. Cloning and molecular characterization of the novel human melanin-concentrating hormone receptor MCH2. Mol Pharmacol 60:632-639.
71. Roy M, David NK, Danao JV, Baribault H, Tian H, Giogetti M. 2005. Genetic inactivation of melanin-concentrating hormone receptor subtype 1 (MCHR1) in mice exerts anxiolytic-like behavioral effects. Neuropsychopharmacology, published online June 29.
72. 1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 39:1413-1421.
73. Russo-Neustadt A, Beard RC, Cotman CW. 1999. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 21:679-682.
74. Sailer AW, Sano H, Zeng Z, McDonald TP, Pan J, Pong S-S, Feighner SD, Tan CP, Fukami T, Iwaasa H, Hreniuk DL, Morin NR, Sadowski SJ, Ito M, Ito M, Banzal A, Ky B, Figueroa DJ, Jiang Q, Austin CP, MacNeil DJ, Ishihara A, Ihara M, Kanatani A, Van der Ploeg LHT, Howard AD, Liu Q. 2001. Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc Natl Acad Sci USA 98:7564-7569.
75. Saito Y, Nothacker H-P, Wang Z, Lin SHS, Leslie F, Civelli O. 1999. Molecular characterization of the melanin-concentrating-hormone receptor. Nature 400:265-269.
76. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R. 2003. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809.
77. Schildkraut JJ. 1965. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509-522.
78. Segal-Lieberman G, Bradley RL, Kokkotou E, Carlson M, Trombly DJ, Wang X, Bates S, Myers MG Jr, Flier JS, Maratos-Flier E. 2003. Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype. Proc Natl Acad Sci USA 100:10085-10090.
79. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. 1998. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396:670-674.
80. Smith DG, Tzavara ET, Shaw J, Luecke S, Wade M, Davis R, Salhoff C, Nomikos GG, Gehlert DR. 2005. Mesolimbic dopamine super-sensitivity in melanin-concentrating hormone-1 receptor-deficient mice. J Neuroscience 25:914-922.
81. Soners AJ, Gao J, Wodka D, Judd AS, Mulhern MM, Napier, JJ, Brune ME, Bush EN, Brodjian S, Dayton BD, Shapiro R, Hernandez LE, Marsh KC, Sham HL, Collins CA, Kym PR. 2005a. Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Bioorg Med Chem Lett 15:2752-2757.
82. Soners AJ, Gao J, Brune M, Bush E, Wodka D, Vasudevan A, Judd AS, Mulhern M, Brodjian S, Dayton B, Shapiro R, Hernandez LE, Marsh KC, Sham HL, Collins CA, Kym PR. 2005b. Identification of 2-(4-benzyloxyphenyl)-N-[1-(2-pyrrolidin-1- yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity. J Med Chem 48:1318-1321.
83. Steffens DC, Krishnan KRR, Helms MJ. 1997. Are SSRIs better that TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 6:10-18.
84. Stunkard A, Faith MS, Allison KC. 2004. Depression and obesity: a complex relationship. Psychiatric Times volume 21, issue 11. Available online at www.psychiatrictimes.com.
85. Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P. 2002. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA 99:3182-3187.
86. Takekawa S, Asami A, Ishihara Y, Terauchi J, Kato K, Shimomura Y, Mori M, Murakoshi H, Kato K, Suzuki N, Nishimura O, Fujino M. 2002. T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur J Pharmacol 438:129-135.
87. Vasudevan A, Verzal MK, Wodka D, Soners AJ, Blackburn C, Che JL, Lai S, Brodjian S, Falls DH, Dayton BD, Govek E, Daniel T, Geddes B, Marsh KC, Hernandez LE, Collins CA, Kym PR. 2005. Identification of aminopiperidine benzamides as MCHr1 antagonists. Bioorg Med Chem Lett 15:3412-3416.
88. Voikar V, Koks S, Vasar E, Rauvala H. 2001. Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. Physiol Behav 72:271-281.
89. Wang S, Behan J, O'Neill K, Weig B, Fried S, Laz T, Bayne M, Gustafson E, Hawes BE. 2001. Identification and pharmacological characterization of a novel human melanin-concentrating hormone receptor, MCH-R2. J Biol Chem 276:34664-34670.
90. Waters GS, Pories WJ, Swanson MS, Meelheim HD, Flickinger EG, May HJ. 1991. Long-term studies of mental health after the Greenville gastric bypass operation for morbid obesity. Am J Surg 161:154-158.
91. World Health Organization. 2001. Mental and neurological disorders. Fact sheet no. 265.
92. Zhou D, Shen Z, Strack AM, Marsh DJ, Shearman LP. 2005. Enhanced running wheel activity of both Mch1r- and Pmch-deficient mice. Regul Pept 124:53-63.